SALT LAKE CITY, Sept. 21, 2021 /PRNewswire/
-- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a
molecular diagnostics company with a unique, patented platform for
the development of molecular diagnostic tests, announced today that
Company representatives will be presenting at the 5th
Advances in Circulating Tumor Cells (ACTC) conference in Kalamata,
Greece, held on September 22-25, 2021.
Co-Diagnostics' Logix Smart™ COVID-19 Tests have also been
selected to be used for on-site testing for conference attendees,
following recent and ongoing efforts to strengthen the Company's
presence and distribution reach across the continent.
In addition to the presentation, which will be conducted at
14:50 local time on Thursday, September
23rd, Co-Diagnostics representatives expect to
meet with new and existing customers and showcase the products
available for sale in the region. European distributors or
laboratories interested in learning more about these products may
contact the Company at info@codiagnostics.com.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets a
state-of-the-art diagnostics technology. The Company's technology
is utilized for tests that are designed using the detection and/or
analysis of nucleic acid molecules (DNA or RNA). The Company also
uses its proprietary technology to design specific tests to locate
genetic markers for use in industries other than infectious disease
and license the use of those tests to specific customers.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-present-at-actc-liquid-biopsy-conference-in-kalamata-greece-301381915.html
SOURCE Co-Diagnostics